

# Press release



*U-Protein Express acquires patent rights on mutated human surfactant protein D as broad anti-influenza therapeutic from the Utrecht University.*

Utrecht, The Netherlands, April 24th 2016 – U-Protein Express, a dedicated service provider in the field of expression and purification of recombinant proteins, announces that it has acquired the patent rights on mutated human surfactant protein D as broad anti-influenza therapeutic from the Utrecht University, The Netherlands. The company will now seek partners to co-develop this innate immunity protein further into a novel anti-viral therapeutic.

About U-Protein Express. U-Protein Express is a dedicated provider in the field of expression and purification of recombinant proteins antibodies. Fully post-translational modified mammalian proteins can be produced via the proprietary r-PEx technology (patent pending). In addition, E. coli and P. pastoris expression platforms are available for the production of more simple proteins. Produced recombinant proteins are purified in house by state-of-the-art purification technology. Main customers are academia, biotech- and pharma companies. For more information on U-Protein Express contact Dr. Martin Helsing at [M.Helsing@U-ProteinExpress.com](mailto:M.Helsing@U-ProteinExpress.com), or visit our website <http://www.U-ProteinExpress.com>.